5 Overlooked Penny Stocks to Buy Right Now

In this article, we will list the 5 Overlooked Penny Stocks to Buy Right Now. Please visit 10 Overlooked Penny Stocks to Buy Right Now if you’d like to see an extended list and how we came up with the list of overlooked penny stocks to buy.

5. Opus Genetics, Inc. (NASDAQ:IRD)

Number of Hedge Fund Holders: 23

Upside Potential: 139.23%

Opus Genetics, Inc. (NASDAQ:IRD), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. A bullish new analyst call and a broadening gene therapy pipeline are boosting confidence in the stock’s outlook.

On June 23, 2026, RBC Capital initiated coverage of Opus Genetics, Inc. (NASDAQ:IRD) with an “Outperform” rating and a $10 price target. The analyst called the setup favorable amid limited competition, de-risked science, and what the firm described as recent FDA leniency. The note projected upside tied to the upcoming BEST1 data readout in September and four more clinical pipeline readouts expected in 2027.

That upside case follows a Research and Development Science Forum Opus Genetics, Inc. (NASDAQ:IRD) hosted on June 16, 2026, where management detailed three new programs entering clinical testing alongside recent LCA5 and BEST1 clinical data. Management also discussed the global IRD market opportunity, as well as its clinical development and execution strategies.

CEO George Magrath said Opus Genetics, Inc. (NASDAQ:IRD) holds first-mover advantage across multiple indications, backed by broad intellectual property protection and rare-disease regulatory pathways that may allow for accelerated approval. In the ongoing Phase 1/2 trial for LCA5, visual acuity improved and was maintained in the adult cohort over 24 months, with dosing for the pivotal Phase 3 trial expected to start in the fourth quarter of 2026.

For BEST1, dosing in the first cohort was completed in May 2026, with three-month topline data expected in September 2026. Two additional programs, OPGx-RDH12 and OPGx-MERTK, are scheduled to begin clinical testing in late 2026 and early 2027, respectively.

Opus Genetics, Inc. (NASDAQ:IRD) shares are up nearly 110% year-to-date as of July 2, 2026.

Opus Genetics, Inc. (NASDAQ:IRD) is engaged in the research and development of ophthalmic biopharmaceutical products, with a focus on developing and commercializing therapies for several eye disorders.